Courier Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.05M Sell
35,523
-281
-0.8% -$16.1K 0.1% 169
2026
Q1
$2.17M Sell
35,804
-344
-1% -$20.1K 0.12% 155
2025
Q4
$1.95M Sell
36,148
-1,100
-3% -$52.9K 0.11% 158
2025
Q3
$1.68M Sell
37,248
-1,098
-3% -$51.3K 0.1% 177
2025
Q2
$1.78M Sell
38,346
-1,563
-4% -$76.7K 0.11% 159
2025
Q1
$2.43M Buy
39,909
+1,470
+4% +$85.7K 0.16% 132
2024
Q4
$2.17M Sell
38,439
-4,607
-11% -$257K 0.15% 128
2024
Q3
$2.23M Sell
43,046
-974
-2% -$45.7K 0.15% 132
2024
Q2
$1.83M Sell
44,020
-610
-1% -$27.3K 0.15% 116
2024
Q1
$2.42M Sell
44,630
-1,883
-4% -$95.9K 0.18% 117
2023
Q4
$2.39M Sell
46,513
-729
-2% -$38.3K 0.18% 114
2023
Q3
$2.74M Sell
47,242
-2,713
-5% -$166K 0.23% 97
2023
Q2
$3.19M Buy
49,955
+7,537
+18% +$505K 0.25% 89
2023
Q1
$2.94M Sell
42,418
-1,317
-3% -$92.9K 0.32% 65
2022
Q4
$3.15M Sell
43,735
-346
-0.8% -$26.1K 0.36% 62
2022
Q3
$3.13M Buy
44,081
+2,659
+6% +$193K 0.39% 60
2022
Q2
$3.19M Buy
41,422
+1,880
+5% +$143K 0.37% 64
2022
Q1
$2.89M Sell
39,542
-3,600
-8% -$242K 0.29% 81
2021
Q4
$2.69M Buy
43,142
+631
+1% +$37K 0.25% 86
2021
Q3
$2.52M Buy
42,511
+24
+0.1% +$1.58K 0.24% 87
2021
Q2
$2.84M Buy
42,487
+1,020
+2% +$66.5K 0.27% 84
2021
Q1
$2.62M Buy
41,467
+992
+2% +$61.7K 0.26% 82
2020
Q4
$2.51M Buy
40,475
+866
+2% +$53.3K 0.27% 78
2020
Q3
$2.53M Sell
39,609
-160
-0.4% -$9.63K 0.3% 76
2020
Q2
$2.35M Sell
39,769
-1,325
-3% -$79.3K 0.3% 74
2020
Q1
$2.49M Sell
41,094
-7,986
-16% -$488K 0.37% 65
2019
Q4
$3.21M Sell
49,080
-1,502
-3% -$86K 0.38% 59
2019
Q3
$2.51M Sell
50,582
-1,051
-2% -$49.4K 0.33% 75
2019
Q2
$2.34M Sell
51,633
-1,952
-4% -$90.9K 0.3% 78
2019
Q1
$2.56M Sell
53,585
-50
-0.1% -$2.49K 0.33% 71
2018
Q4
$2.79M Sell
53,635
-1,255
-2% -$67.4K 0.41% 60
2018
Q3
$3.41M Buy
54,890
+3,432
+7% +$204K 0.42% 60
2018
Q2
$2.85M Buy
51,458
+212
+0.4% +$11.4K 0.37% 69
2018
Q1
$3.24M Buy
51,246
+784
+2% +$50.4K 0.43% 59
2017
Q4
$3.09M Buy
50,462
+114
+0.2% +$7.13K 0.4% 64
2017
Q3
$3.21M Buy
50,348
+8,925
+22% +$521K 0.45% 57
2017
Q2
$2.31M Sell
41,423
-170
-0.4% -$9.25K 0.4% 57
2017
Q1
$2.26M Sell
41,593
-201
-0.5% -$11K 0.4% 58
2016
Q4
$2.44M Buy
41,794
+2,385
+6% +$130K 0.47% 50
2016
Q3
$2.13M Sell
39,409
-1,033
-3% -$66.4K 0.42% 56
2016
Q2
$2.98M Buy
40,442
+602
+2% +$42.5K 0.59% 39
2016
Q1
$2.54M Sell
39,840
-60
-0.2% -$3.78K 0.53% 47
2015
Q4
$2.75M Hold
39,900
0.59% 42
2015
Q3
$2.36M Buy
39,900
+275
+0.7% +$17.4K 0.52% 50
2015
Q2
$2.64M Sell
39,625
-4,021
-9% -$265K 0.53% 47
2015
Q1
$2.81M Sell
43,646
-400
-0.9% -$25K 0.56% 46
2014
Q4
$2.6M Sell
44,046
-800
-2% -$45.1K 0.52% 46
2014
Q3
$2.29M Buy
44,846
+378
+0.9% +$18.9K 0.46% 54
2014
Q2
$2.16M Sell
44,468
-969
-2% -$47.8K 0.43% 61
2014
Q1
$2.36M Sell
45,437
-1,335
-3% -$71K 0.49% 53
2013
Q4
$2.49M Buy
46,772
+1,165
+3% +$59.3K 0.53% 49
2013
Q3
$2.11M Sell
45,607
-1,930
-4% -$84.7K 0.48% 52
2013
Q2
$2.12M Buy
+47,537
New +$2.06M 0.53% 50

Other funds holding BMY

Courier Capital's BMY Position: Q2 2026 in Review

Courier Capital reduced its Bristol-Myers Squibb (BMY) stake by 0.78% in Q2 2026, selling an estimated $16.1K and leaving 35,523 shares worth $2.05M. The position accounts for 0.1% of the portfolio, ranked #169.

Courier Capital first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.41M in Q3 2018. 879 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Courier Capital held 35,523 shares of Bristol-Myers Squibb worth $2.05M as of Q2 2026.
  • Courier Capital sold 281 Bristol-Myers Squibb shares in Q2 2026, an estimated $16.1K.
  • Bristol-Myers Squibb made up 0.1% of Courier Capital's portfolio in Q2 2026, its #169 holding.
  • Courier Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Courier Capital's Bristol-Myers Squibb position peaked at $3.41M in Q3 2018.
  • 879 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Courier Capital's 13F filing for Q2 2026, filed 16 Jul 2026.